TOKYO--(BUSINESS WIRE)--PHC Corporation Biomedical Division (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura, hereinafter referred to as "Biomedical Division") will showcase a prototype ...
CAMBRIDGE, England & BAD HOMBURG, Germany--(BUSINESS WIRE)--Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that ...
SAN DIEGO—Cytiva has launched its Sefia next-generation manufacturing platform, with the goal of helping drug developers and larger healthcare providers accelerate their production of chimeric antigen ...
Data integrity is key to the success of any cell therapy program. CDMOs can implement robust data management systems for manufacturing that provide secure, real-time access to data, which can help ...
Cellares unveiled Cell Q Thursday, the first automated quality control (QC) workcell for cell therapy manufacturing. According to the company, Cell Q complements its Cell Shuttle Platform by ...
Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and the Cell and Gene Therapy Catapult (CGT Catapult), an ...
A study has developed an innovative method that overcomes the limitations of traditional additive manufacturing (3D printing), significantly simplifying and accelerating the production of ...
Emily Whitehead made the history books in 2012 when she become the first pediatric patient with B-cell acute lymphoblastic leukemia to be given a chimeric antigen receptor (CAR) T-cell therapy. After ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results